Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Zachary Veitch"'
Autor:
Alexi Campbell, Sharlene Gill, Desiree Hao, Erin Powell, Stephanie Snow, Zachary Veitch, Stephen Welch
Publikováno v:
Current Oncology, Vol 30, Iss 8, Pp 7581-7607 (2023)
On behalf of the Canadian Association of Medical Oncologists, we are pleased to present the abstracts of the 2023 Annual Scientific Meeting. The CAMO Annual Scientific Meeting (ASM) took place on 27 April 2023 in an in-person event in Toronto, ON. Th
Externí odkaz:
https://doaj.org/article/ee60ff12e5d941c0b1f7a2bb115411f5
Autor:
Carlos E. Stecca, Di Maria Jiang, Zachary Veitch, Sebastian J Hotte, Nimira Alimohamed, Lori Wood, Srikala S. Sridhar
Publikováno v:
Clinical Genitourinary Cancer. 21:273-277
In metastatic hormone sensitive prostate cancer (mHSPC), treatment intensification with either docetaxel or an androgen-receptor-axis targeted therapy (ARAT), added to androgen deprivation therapy (ADT) is the new standard of care. To better understa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::42afcbcfdb2594297d48b555e5e5f15c
https://doi.org/10.1016/j.clgc.2022.11.020
https://doi.org/10.1016/j.clgc.2022.11.020
Publikováno v:
Journal of the National Comprehensive Cancer Network. 21:QIM23-129
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5b65efad1fdd4af9872badcac53c98e5
https://doi.org/10.6004/jnccn.2022.7118
https://doi.org/10.6004/jnccn.2022.7118
Autor:
Zachary Veitch, Domen Ribnikar, Derek Tilley, Patricia A. Tang, Karen King, Philippe L. Bedard, Sasha Lupichuk, David W. Cescon
Publikováno v:
Br J Cancer
BACKGROUND: Long-term response to HER2-targeted therapies is infrequent in metastatic breast cancer (MBC). We evaluated clinical characteristics of HER2-positive MBC patients with no evidence of disease (NED) vs residual disease (RES) experiencing lo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10e208dc6b69bf23773bd59678939b7f
https://doi.org/10.1038/s41416-021-01676-4
https://doi.org/10.1038/s41416-021-01676-4
Autor:
Mitchell J. Elliott, Zachary Veitch, Philippe Bedard, Eitan Amir, Aaron Dou, Jesus Fuentes Antras, Michelle Nadler, Nicholas Meti, Nancy Gregorio, Elizabeth Shah, Helen Chow, Nathan Campbell, Samantha Terrell, Charlene Knape, Karen Howarth, Lillian Siu, Hal Berman, David W. Cescon
Publikováno v:
Cancer Research. 83:P6-01
Background: ctDNA dynamics are associated with treatment response, and ctDNA detection following treatment is associated with disease recurrence in early breast cancer (EBC). Highly sensitive assays may permit effective risk stratification and guide
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d63142ab933b1973bd45a62e4d88c513
https://doi.org/10.1158/1538-7445.sabcs22-p6-01-16
https://doi.org/10.1158/1538-7445.sabcs22-p6-01-16
Publikováno v:
Breast cancer research and treatment. 194(3)
Older women are poorly represented in trials evaluating chemotherapy for breast cancer (BC). This study aimed to describe survival and associated factors among elderly women receiving chemotherapy for non-metastatic BC.This was a population-based coh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dcbd61aa0d00bd62000e9ea5e6750744
https://pubmed.ncbi.nlm.nih.gov/35731453
https://pubmed.ncbi.nlm.nih.gov/35731453
Autor:
Alona Zer, David Hogg, Maryam Masood, Samer Salah, Herbert H. Loong, George S. Charames, Zachary Veitch, Rita A. Kandel, Penelope A. Bradbury, Andrew Wong, Albiruni Ryan Abdul Razak, Abha A. Gupta
Publikováno v:
Scientific Reports, Vol 9, Iss 1, Pp 1-9 (2019)
Scientific Reports
Scientific Reports
ENMD-2076, an aurora-A kinase inhibitor with anti-angiogenic properties, has shown activity in solid and hematologic malignancies. We investigated oral ENMD-2076 in an open-label, single-arm phase II study using 275 mg daily on a 28-day cycle in pati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7de30e93f436d6a618a8c38f5dc2012d
https://doi.org/10.1038/s41598-019-43222-6
https://doi.org/10.1038/s41598-019-43222-6
Autor:
Stacey L. Hembruff, Baoqing Guo, Zachary Veitch, Amadeo M. Parissenti, Monique L Laberge, David J. Villeneuve, Melanie Cecchetto
Publikováno v:
BMC Cancer, Vol 8, Iss 1, p 318 (2008)
BMC Cancer
BMC Cancer
Background Anthracyclines and taxanes are commonly used in the treatment of breast cancer. However, tumor resistance to these drugs often develops, possibly due to overexpression of drug transporters. It remains unclear whether drug resistance in vit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41da29a408f02e15228031b092041397
http://www.biomedcentral.com/1471-2407/8/318
http://www.biomedcentral.com/1471-2407/8/318
Autor:
Stacey L. Hembruff, Jamei Eng, David J. Villeneuve, Baoqing Guo, Zachary Veitch, Amadeo M. Parissenti
Publikováno v:
Anti-cancer drugs. 18(5)
Genome profiling approaches such as cDNA microarray analysis and quantitative reverse transcription polymerase chain reaction are playing ever-increasing roles in the classification of human cancers and in the discovery of biomarkers for the predicti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fb3f03e588525cbd70c5ddb55cc567a2
https://pubmed.ncbi.nlm.nih.gov/17414620
https://pubmed.ncbi.nlm.nih.gov/17414620
Autor:
William A. Dew, Amadeo M. Parissenti, Zachary Veitch, Melanie Cecchetto, Stacey L. Hembruff, David J. Villeneuve
Publikováno v:
Breast cancer research and treatment. 96(1)
cDNA microarray analysis is a highly useful tool for the classification of tumors and for prediction of patient prognosis to specific cancers based on this classification. However, to date, there is little evidence that microarray approaches can be u
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::09a446dff6b6d112993c49b0844d6e86
https://pubmed.ncbi.nlm.nih.gov/16322897
https://pubmed.ncbi.nlm.nih.gov/16322897